CEO Executive AssistantResearch and development is where pharmaceutical value is created. Discovery programs, lead optimization, preclinical studies, and translational research all require scientific expertise, rigorous process management, and strategic investment decisions. The pharma CEO who tries to personally manage R&D operations is not only over-extended; they are displacing scientific leadership that produces better outcomes.
This framework helps pharma CEOs establish effective R&D delegation that drives pipeline productivity while maintaining appropriate strategic oversight.
The CEO’s R&D Strategic Role
Portfolio strategy and investment allocation. The CEO, working with the Chief Scientific Officer and board, determines how R&D resources are allocated across therapeutic areas, development stages, and internal versus external programs. These decisions define the company’s long-term value.
R&D budget and resource commitments. Total R&D investment, major platform investments, and significant external collaboration commitments require CEO-level approval.
Pipeline communications to investors and partners. The CEO communicates pipeline progress, key milestones, and R&D strategy to investors, partners, and media.
External scientific relationships at the strategic level. Relationships with academic institutional leaders, major collaboration partners, and key scientific advisors at the strategic level require CEO engagement.
R&D leadership accountability. The CEO holds the CSO, CMO, and Head of Research accountable for pipeline productivity and scientific quality.
R&D Delegation Framework
To the Chief Scientific Officer
The CSO is the CEO’s primary R&D delegation partner:
Discovery and early research leadership. The CSO leads scientific strategy for discovery programs, target identification, lead compound selection, and early-stage optimization decisions.
R&D portfolio management. The CSO manages the research portfolio through development stage gates, ensuring scientific rigor and resource appropriateness at each stage.
External scientific collaborations. Academic partnerships, research collaborations with universities, and scientific advisory board management are CSO responsibilities.
Research platform technology. Decisions about scientific platforms (genomics, AI-driven drug discovery, protein engineering) are CSO-led with CEO alignment on major investments.
Scientific talent strategy. Recruiting and retaining top scientific talent, building scientific culture, and developing scientific leadership are CSO responsibilities.
To the Head of Preclinical Development
IND-enabling studies. Designing and executing the preclinical safety studies required to support clinical development is a preclinical function.
ADME and pharmacology studies. Absorption, distribution, metabolism, and excretion studies are managed by the preclinical team.
Preclinical vendor management. Managing CRO relationships for preclinical studies and animal studies is a preclinical operations function.
To the Head of Translational Medicine
Biomarker strategy. Identifying and validating biomarkers for patient selection, disease monitoring, and proof-of-concept is a translational medicine function.
Patient stratification strategies. Developing strategies for selecting patient populations likely to benefit from a compound is a translational medicine responsibility.
To Program Teams
For each compound or program in the pipeline, a cross-functional program team typically manages project execution, timeline, budget, and deliverables. Program teams report through the CSO or CMO, not directly to the CEO.
Portfolio Review and Governance
Portfolio Review Committee
A monthly or quarterly portfolio review committee evaluates program progress against predefined criteria, makes stage gate decisions, and manages the portfolio strategically. The CEO may participate in quarterly portfolio reviews for major decisions; routine portfolio management meetings proceed without CEO attendance.
R&D Dashboard for CEO
A monthly R&D summary for the CEO covers:
- Pipeline program status and recent milestones
- Key upcoming data readouts or decision points
- R&D budget utilization versus plan
- Major external collaborations status
- Scientific talent highlights
Stage Gate Decision Process
Formal stage gate criteria for advancing compounds from discovery through preclinical to clinical stages should be documented and applied consistently by scientific leadership. The CEO participates in major stage gate decisions for high-value or high-priority programs; the CSO manages routine stage gate decisions.
For pharma CEOs building comprehensive R&D and clinical delegation models, delegation guide for pharma CEO: clinical operations provides the clinical-stage complement to this framework.
Broader pharmaceutical executive delegation models are covered in what pharmaceutical biotech CEOs delegate to their chief of staff.
Balancing Scientific Autonomy with CEO Accountability
One of the greatest delegation challenges in pharmaceutical R&D is managing the tension between scientific autonomy and organizational accountability. Scientists perform best when they have intellectual freedom. But unchecked scientific programs can consume capital without producing commercially viable assets.
The CEO resolves this tension by:
- Setting clear commercial criteria (target product profiles) that guide scientific programs
- Establishing rigorous portfolio review processes that evaluate scientific progress against strategic criteria
- Investing in strong CSO leadership that can bridge scientific excellence with commercial accountability
- Ensuring R&D investment decisions are informed by commercial, regulatory, and competitive context
This requires CEO engagement at the portfolio governance level without CEO intrusion into scientific decision-making.
Conclusion
Pharmaceutical R&D productivity depends on deep scientific expertise, disciplined portfolio management, and sufficient investment. The pharma CEO who establishes clear scientific leadership, maintains rigorous portfolio governance, and communicates pipeline strategy effectively can drive R&D value creation without managing discovery programs personally.
Trust the science team. Govern the portfolio. Invest in the right programs. Communicate the vision.
For pharmaceutical R&D strategy and productivity insights, see McKinsey.com/industries/life-sciences.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.